Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW. Eiring AM, et al. Among authors: khorashad js. Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Leukemia. 2015. PMID: 25134459 Free PMC article.
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS. Bazeos A, et al. Among authors: khorashad js. Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. Leukemia. 2010. PMID: 20445576 No abstract available.
Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JA, Wang M, Karran L, Dyer MJ, Forrest D, Page K, Eaves CJ, Woolfson A. Grant H, et al. Among authors: khorashad js. Leukemia. 2010 Oct;24(10):1817-21. doi: 10.1038/leu.2010.179. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739956 No abstract available.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: khorashad js. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
Advances in the treatment of chronic myeloid leukemia.
Eiring AM, Khorashad JS, Morley K, Deininger MW. Eiring AM, et al. Among authors: khorashad js. BMC Med. 2011 Aug 26;9:99. doi: 10.1186/1741-7015-9-99. BMC Med. 2011. PMID: 21867560 Free PMC article. Review.
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW. Khorashad JS, et al. Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5. Blood. 2013. PMID: 23223358 Free PMC article.
New concepts for CML clonality.
Khorashad JS, Deininger MW, O'Hare T. Khorashad JS, et al. Oncotarget. 2013 Jan;4(1):7-8. doi: 10.18632/oncotarget.882. Oncotarget. 2013. PMID: 23448894 Free PMC article. No abstract available.
74 results